KP10 10mg*10vials

KPV KP10 10mg x 10 Vials

Product Overview

KPV KP10 is an upgraded anti-inflammatory and immunomodulatory tripeptide (lysine-proline-valine) in the repair peptide category, serving as an enhanced intermediate version of the basic KP5 5mg product. This optimized short-chain tripeptide is derived from the bioactive core fragment of endogenous alpha-MSH, exhibiting zero immunogenicity, excellent biochemical stability, and a receptor-independent targeted inflammatory suppression mechanism. Compared to the standard version, KP10 10mg has doubled the effective concentration, enhancing NF-kappa B and MAPK dual inflammatory pathway inhibition, mucosal repair, neuroinflammatory stabilization, and immune homeostasis regulation. This upgraded barrier-enhancing formulation supports deeper inflammatory microenvironment purification and stronger barrier reconstruction capacity. It is designed for moderate chronic inflammatory lesion modeling, intestinal mucosal damage intervention, recurrent skin inflammation regulation, and peptide complex synergistic anti-inflammatory studies, serving as an upgraded preclinical research material for inflammatory pharmacology and barrier immune mechanism research.

Core Research Functions

Chronic Persistent Inflammation Inhibition: Supports deep inhibition of chronic persistent inflammation research and pro-inflammatory cytokine and chemokine overexpression inhibition studies.

Mucosal and Intestinal Barrier Damage Reconstruction: Supports enhanced mucosal and intestinal barrier damage reconstruction research.

Recurrent Skin Inflammatory Lesion Intervention: Supports recurrent skin inflammatory lesion relief research.

Systemic Immune Homeostasis Stabilization: Supports long-term systemic immune homeostasis stabilization research.

Unlike the mild basal regulatory effect of KP5, KP10 10mg exhibits faster experimental phenotypic responses, stronger inflammatory signal blocking efficiency, and more durable barrier repair efficacy. It supports moderately refractory inflammatory phenotype research, including recurrent dermatitis, persistent mucosal erosion, and low-grade inflammatory infiltration. It supports I-kappa B protein activity stabilization, NF-kappa B excessive nuclear translocation prevention, and inflammatory gene transcription inhibition research; simultaneously supports glial cell excessive activation inhibition, moderate neuroinflammatory stress reduction, and nerve and epithelial tissue physiological stability protection research. The 10mg balanced formulation supports medium-to-high dose gradient threshold screening, moderate inflammatory disease mechanism modeling, and complex peptide synergistic anti-inflammatory effect validation, providing high-precision, reproducible data for in-depth inflammatory immunology research.

Key Advantages

Enhanced Potency Targeted Inflammation Inhibition: The effective concentration is doubled compared to the standard 5mg dose, enhancing NF-kappa B and MAPK dual pathway inhibitory capacity, exceeding the limited efficacy range of the basic low-dose KPV formulation.

Independent High-Precision Anti-inflammatory Mechanism: Possesses receptor-independent transcriptional-level inflammatory regulation characteristics, supporting pathological inflammation inhibition research without normal immune function interference, achieving high-precision inflammatory homeostasis intervention without immunosuppressive side effects.

Enhanced Barrier Repair and Neuroinflammatory Dual Repair: Further enhances skin and intestinal mucosal barrier reconstruction capacity, while simultaneously enhancing moderate neuroinflammatory inflammation relief, covering moderate-to-deep inflammatory damage repair research scenarios that exceed basic formulation ranges.

High-Stability Pharmaceutical-Grade Purification Process: Utilizes upgraded multi-stage gradient deep purification and vacuum lyophilization technology, preserving active molecular structure with minimal impurity interference and high-purity experimental variables, ensuring accuracy and reproducibility of high-level research conclusions.

Advanced Standard Aseptic Packaging: 10 vials per integrated dust-free aseptic package. Each batch undergoes rigorous full-item HPLC purity testing and is accompanied by a complete Certificate of Analysis (COA). With long-term stable activity retention, it is suitable for high-level laboratory inflammation mechanism research, high-standard barrier immunity preclinical projects, and customized bulk procurement.

Specifications and Quality Control

Format: Lyophilized powder, 10mg per vial. Packaging: 10 vials per pack, dust-free aseptic integrated container. Purity Testing: Full HPLC purity verification with complete Certificate of Analysis (COA).